Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor presented as a sterile intravenous solution for intravenous use. It replaces deficient factor VIII to manage bleeding episodes in patients with hemophilia A, a congenital factor VIII deficiency.

GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures product integrity through temperature‑controlled logistics and regulatory adherence, enabling reliable access for patients across the EU and other markets.

Octanate is used to replace deficient factor VIII in the intrinsic pathway of the coagulation cascade for hemophilia A management.

- Hemophilia A (congenital factor VIII deficiency): prevents and controls bleeding episodes in affected patients. - Severe hemophilia A: provides prophylactic factor replacement to reduce spontaneous bleeds. - Surgical procedures in hemophilia A patients: ensures hemostasis during and after surgery.

Common Side Effects: - Infusion‑related reactions (e.g., chills, fever, headache) - Nausea or vomiting - Arthralgia or joint pain - Mild rash at infusion site - Transient increase in liver enzymes - Fatigue or malaise

Serious or Rare Side Effects: - Development of inhibitory antibodies (inhibitors) against factor VIII - Anaphylactic or severe allergic reactions - Thrombotic events (e.g., deep‑vein thrombosis) - Hemolysis or renal impairment - Severe hypotension during infusion - Disseminated intravascular coagulation (rare).

Before initiating therapy, consider the following precautions: - Monitor for inhibitor development: regularly assess factor VIII activity and inhibitor titres. - Assess bleeding risk: evaluate patient history and concurrent anticoagulant use. - Use aseptic technique: ensure sterile preparation and administration. - Avoid in patients with known hypersensitivity to any component of the product. - Adjust dosing in patients with severe hepatic or renal impairment as clinically indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanate may interact with other hemostatic agents. Monitor patients closely for additive effects.

Major Interactions (Avoid): - Concurrent use of bypassing agents (e.g., activated prothrombin complex concentrate) may increase thrombosis risk. - Immunosuppressive therapy that may alter inhibitor formation.

Moderate Interactions (Monitor Closely): - Antifibrinolytics (e.g., tranexamic acid) can enhance hemostasis and may require dose adjustment. - Concomitant anticoagulants (e.g., warfarin) may counteract the therapeutic effect and need careful monitoring. - Certain antibiotics (e.g., rifampin) may affect protein metabolism, requiring observation.